Influence of cannabis use on incidence of psychosis in people at clinical high risk
Abstract Aims: Evidence for case–control studies suggests that cannabis use is a risk factor for the development of psychosis. However,…
Edward Chesney
The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment
Abstract Background and Aims: Long‐term harms of cannabis may be exacerbated in adolescence, but little is known about the acute…
Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios
Abstract As countries adopt more permissive cannabis policies, it is increasingly important to identify strategies that can reduce the harmful…
Acceptability of cannabidiol in patients with psychosis
Abstract Background: Cannabidiol (CBD) is a promising novel candidate treatment for psychosis. It has a more benign side effect profile…
Cannabidiol (CBD) as a novel treatment in the early phases of psychosis
Abstract The pharmacological interventions available for individuals in the early stages of psychosis are extremely limited. For those at clinical…
Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products
Abstract Over the past 5 years, public interest in the potential health benefits of cannabidiol (CBD) has increased exponentially, and…
Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials
Abstract Cannabidiol (CBD) is being investigated as a treatment for several medical disorders but there is uncertainty about its safety.…